Andrew Combs Prelude Therapeutics Inc (PRLD) insider trading activity

PRLD Quotes by TradingView

Andrew Combs is Chief Chemistry Officer of Prelude Therapeutics Inc. Currently has a direct ownership of 377,623 shares of PRLD, which is worth approximately $430,490. The most recent transaction as insider was on Dec 23, 2024, when has been sold 60,000 shares (Common Stock) at a price of $1.37 per share, resulting in proceeds of $82,200. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 378K
24.04% 3M change
24.04% 12M change
Total Value Held $430,490

Andrew Combs Transaction History

Date Transaction Value Shares Traded Shares Held Form
Dec 23 2024
BUY
Open market or private purchase
$82,200 $1.37 p/Share
60,000 Added 13.71%
377,623 Common Stock
Dec 20 2024
BUY
Open market or private purchase
$3,536 $1.15 p/Share
3,075 Added 0.96%
317,623 Common Stock
Mar 31 2022
BUY
Exercise of conversion of derivative security
$68,157 $1.89 p/Share
36,062 Added 10.59%
304,442 Common Stock
Dec 14 2021
BUY
Open market or private purchase
$46,400 $11.6 p/Share
4,000 Added 1.47%
268,380 Common Stock
Dec 13 2021
BUY
Open market or private purchase
$48,480 $12.12 p/Share
4,000 Added 1.49%
264,380 Common Stock
AC

Andrew Combs

Chief Chemistry Officer
Wilmington, DE

Track Institutional and Insider Activities on PRLD

Follow Prelude Therapeutics Inc and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells PRLD shares.

Notify only if

Insider Trading

Get notified when an Prelude Therapeutics Inc insider buys or sells PRLD shares.

Notify only if

News

Receive news related to Prelude Therapeutics Inc

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on PRLD